)

Apogee Therapeutics (APGE) investor relations material
Apogee Therapeutics Stifel Virtual Immunology and Inflammation Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key presentations and data highlights
Presented three abstracts at EADV, including a late breaker with new phase 2 data for an IL-13 antibody in atopic dermatitis (AD).
Phase 2a data showed 66.9% EZ75 response and significant itch relief as early as one week, with only four dosing days.
Safety profile aligned with existing therapies; conjunctivitis rates similar to Dupixent and no injection site reactions reported.
Ongoing phase 2b study is testing three doses, with a mid-2026 readout planned.
Maintenance study will report in the first half of next year, focusing on sustained response with quarterly or semiannual dosing.
Market landscape and competitive positioning
Biologic market for AD is growing rapidly, with 25% overall growth and 48% increase in new-to-brand prescriptions year-over-year.
Recent launches of Eblis and Nimluvio have outperformed previous benchmarks in their first year.
Despite a crowded market, frontline therapy remains dominated by Dupixent, with new entrants mainly competing in later lines.
Market research suggests strong physician interest in a new therapy with a quarterly dosing schedule and efficacy comparable or superior to current options.
Forward-looking statements and development plans
Phase 2b and maintenance studies are progressing, with no safety concerns reported.
Combination therapy approach is being pursued, with a head-to-head study ongoing and readout expected in the second half of next year.
Company is prioritizing atopic dermatitis but also planning expansion into respiratory indications, starting with asthma.
Strong cash position ($620M) provides runway into 2028, supporting late-stage development and expansion plans.
Plans to launch the lead therapy as a monotherapy in AD by 2029, with additional expansion and combination data to be announced.
Next Apogee Therapeutics earnings date

Next Apogee Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage